Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 1.00 |
| ▸ | TP53 | P04637 | 5/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.66 |
| ▸ | HPGD | P15428 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24711203 | 0.83 | MAPT (0.70) | MAPTTP53SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL24711778 | 0.81 | MAPT (0.68) | MAPTTP53SMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL24711202 | 0.80 | MAPT (0.66) | MAPTTP53SMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL4361940 | 0.79 | SMN1; SMN2 (1.00) | MAPTTP53SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL24711515 | 0.78 | TP53 (0.80) | MAPTTP53SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL24711185 | 0.75 | MAPT (0.60) | MAPTTP53SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL24710830 | 0.74 | MAPT (0.71) | MAPTTP53SMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL27202488 | 0.73 | DDX3X (0.73) | MAPTTP53SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL24710982 | 0.72 | TP53 (0.75) | MAPTTP53SMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL14275901 | 0.70 | MAPT (0.76) | MAPTTP53SMN1; SMN2HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220395500-A1 | SMALL MOLECULE ACTIVATORS OF INTERFERON REGULATORY FACTOR 3 AND METHODS OF USE THEREOF | NEURALEXO, INC. | 2022-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220395500-A1 | SMALL MOLECULE ACTIVATORS OF INTERFERON REGULATORY FACTOR 3 AND METHODS OF USE THEREOF | IRF3, IRF2BP2, STAT1 | MAPT 4038/4885TP53 673/4885SMN1; SMN2 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.